Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

Objectives: A phase 1, double-blind, placebo-controlled trial was conducted to evaluate the safety, tolerability, and exploratory efficacy of repeat monthly doses of subcutaneous (SC) casirivimab and imdevimab (CAS+IMD) in uninfected adult volunteers. Methods: Participants were randomized (3:1) to S...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, Wenjun Zheng, Scott Rasmussen, Danielle Armas, Masaru Oshita, Cynthia Brinson, Steven Folkerth, Lori Faria, Ingeborg Heirman, Neena Sarkar, Bret J. Musser, Shikha Bansal, Meagan P. O'Brien, Kenneth C. Turner, Samit Ganguly, Adnan Mahmood, Ajla Dupljak, Andrea T. Hooper, Jennifer D. Hamilton, Yunji Kim, Bari Kowal, Yuhwen Soo, Gregory P. Geba, Leah Lipsich, Ned Braunstein, George D. Yancopoulos, David M. Weinreich, Gary A. Herman
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2022-09-01
Serie:	International Journal of Infectious Diseases
Soggetti:	COVID-19 SARS-CoV-2 Monoclonal antibody Casirivimab Imdevimab
Accesso online:	http://www.sciencedirect.com/science/article/pii/S1201971222003800
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!